Literature DB >> 25799164

[The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome].

Jordan Gauthier1, Gandhi Damaj2, Ibrahim Yakoub-Agha3.   

Abstract

Treatment of myelodysplastic syndromes (MDS) remains unsatisfactory. Variable success in the correction of blood cytopenias, reduction of the proportion of marrow myeloblasts, and normalization of cytogenetics has been achieved with a variety of treatment strategies, including the use of immunosuppressive drugs, differentiating agents, conventional chemotherapy, and hypomethylating agents (HMAs) However, in general, responses have not been complete and have been of limited duration; prolongation of survival, if achieved, on average has been in the range of months. Currently, allogeneic hematopoietic stem-cell transplantation (allo-SCT) remains the only approach with curative potential for patients with higher risk/advanced MDS. Yet, despite the beneficial effects of allo-SCT, post-transplant relapse is a major cause of failure. Debulking prior to transplant treatment in patients with MDS is a matter of debate. The achievement of complete remission (CR) before allo-SCT improves post-transplantation outcome, although it is not clear whether this reflects the selection of patients with more responsive disease or is related to a reduction in disease burden. Higher CR rates in patients with MDS are obtained with induction chemotherapy (ICT) than with hypomethylating agents (HMAs), although HMAs may be active in patients with complex karyotypes in whom ICT almost invariably fails. Furthermore, HMAs have a good toxicity profile compared with ICT and may therefore be considered especially in older patients and in patients with comorbidities. However, all interventions aimed at reducing disease burden before allo-SCT expose patients to the risk of complications, which may prevent them from undergoing transplantation. Therefore, up-front allo-SCT is an option, particularly for patients with life-threatening cytopenias. In the absence of prospective randomized trials, the main therapeutic approaches are discussed in this review.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Allograft; Allogreffe; Myelodysplasic syndrome; Réduction tumorale; Syndrome myélodysplasique; Tumor reduction

Mesh:

Substances:

Year:  2015        PMID: 25799164     DOI: 10.1016/j.bulcan.2015.02.009

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.

Authors:  Sang Kyun Sohn; Joon Ho Moon; In Hee Lee; Jae Sook Ahn; Hyeoung Joon Kim; Joo Seop Chung; Ho Jin Shin; Sung Woo Park; Won Sik Lee; Sang Min Lee; Hawk Kim; Ho Sup Lee; Yang Soo Kim; Yoon Young Cho; Sung Hwa Bae; Ji Hyun Lee; Sung Hyun Kim; Ik Chan Song; Ji Hyun Kwon; Yoo Jin Lee
Journal:  Korean J Intern Med       Date:  2017-12-15       Impact factor: 2.884

Review 2.  Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.

Authors:  Liu Liu; Menglu Jia; Ling Sun; Wenliang Tian; Ping Tang; Zhongxing Jiang
Journal:  Clin Exp Med       Date:  2021-04-17       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.